MetaCap

Boundless Bio (BOLD) vs Kazia Therapeutics (KZIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Kazia Therapeutics (KZIA) over the past year, gaining 105.3% versus a loss of 41.1%. Kazia Therapeutics is the larger company by market cap ($56.2 million vs $54.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%KZIA-41.08%
+176%+62%-51%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%KZIA-68.26%
+204%+49%-107%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus KZIA key metrics
MetricBOLDKZIA
Share price$2.32$4.92
Market cap$54.78M$56.22M
1-day change-2.52%-8.38%
YTD return+93.33%-28.59%
1-year return+105.31%-41.08%
5-year return—-99.01%
EPS (TTM)$-2.46$-6.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-58.20M—
52-week high$3.16$17.40
52-week low$0.961$4.50
Distance from 52-week high-26.68%-71.72%
Analyst consensusnonenone
Avg. price target upside+72.41%+476.02%
Average volume131.34K307.30K
Shares outstanding23.61M11.43M
Employees286
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed KZIA by 146.4 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

BOLD vs KZIA FAQ

Which is bigger, Boundless Bio or Kazia Therapeutics?

Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $54.78M for Boundless Bio (BOLD).

Which stock has performed better over the past year, BOLD or KZIA?

BOLD returned +105.31% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and Kazia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons